The universe in an exosome
Versatope is banking on E. coli exosomes and M2 for a universal flu vaccine
Versatope Therapeutics Inc. is using exosomes from commensal E. coli as the backbone of a universal influenza vaccine that should be cheaper and easier to manufacture than other vesicle-based vaccines.
The company’s technology was developed by scientific co-founder David Putnam, a professor of biomedical engineering at Cornell University. Putnam and colleagues engineered non-pathogenic strains of commensal E. coli that produce low levels